Toregem BioPharma is a startup from Kyoto University that develops a treatment and tooth regeneration drug for congential adential.
Toregem BioPharma has raised $5.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2026.
Toregem BioPharma's investors include Kyoto University Innovation Capital, Miraidoa, Kyogin Lease & Capital, Gemseki, Astellas Venture Management.
Toregem BioPharma is headquartered in Kawaramachi, Japan.
Toregem BioPharma is a startup from Kyoto University that develops a treatment and tooth regeneration drug for congential adential.
Toregem BioPharma is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Toregem BioPharma — Funding & Investors." VCBacked, April 27, 2026, https://www.vcbacked.co/company/toregem-biopharma. Accessed July 19, 2026.
VCBacked. (2026). Toregem BioPharma — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/toregem-biopharma
{{cite web |title=Toregem BioPharma — Funding & Investors |url=https://www.vcbacked.co/company/toregem-biopharma |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated